Paper I
2015 February (2010 Scheme) · 40 marks · 120 min

Question

Rationale of using terazosin in benign prostatic hypertrophy

Q101 marksShort Answers

Answer

Terazosin is a selective α1-adrenergic receptor antagonist. In BPH, α1 receptors are densely present in the smooth muscle of the prostate capsule, prostatic urethra, and bladder neck, and their stimulation causes contraction contributing to the dynamic component of bladder outlet obstruction. By blocking α1 receptors, terazosin relaxes this smooth muscle, reducing urethral resistance and improving urine flow — providing rapid symptomatic relief of BPH symptoms without affecting prostate size.

Other Years Asked


Revise MBBS
Preview